Ken Griffin
TRVI icon

Ken Griffin’s Trevi Therapeutics TRVI Stock Holding History

Ken Griffin’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$558K Sell
46,800
-43,200
-48% -$484K ﹤0.01% 9037
2025
Q4 		$1.13M Sell
90,000
-142,000
-61% -$1.64M ﹤0.01% 7129
2025
Q3 		$2.12M Buy
232,000
+146,600
+172% +$1.1M ﹤0.01% 5953
2025
Q2 		$467K Buy
85,400
+57,400
+205% +$357K ﹤0.01% 8791
2025
Q1 		$176K Sell
28,000
-21,500
-43% -$103K ﹤0.01% 10632
2024
Q4 		$204K Buy
49,500
+45,000
+1,000% +$144K ﹤0.01% 10425
2024
Q3 		$15K Buy
+4,500
New +$13.4K ﹤0.01% 12989
2024
Q2 		– Sell
-600
Closed -$2.07K – 15429
2024
Q1 		$2.07K Sell
600
-2,400
-80% -$5.36K ﹤0.01% 14047
2023
Q4 		$4.02K Buy
+3,000
New +$4.54K ﹤0.01% 13537
2023
Q2 		– Sell
-47,400
Closed -$87.7K – 15254
2023
Q1 		$87.7K Buy
47,400
+36,000
+316% +$81.4K ﹤0.01% 11445
2022
Q4 		$22K Buy
+11,400
New +$22.5K ﹤0.01% 13067

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Ken Griffin's TRVI Position: Q1 2026 in Review

Ken Griffin increased its Trevi Therapeutics (TRVI) stake by 686% in Q1 2026, buying an estimated $11.7M and bringing the position to 1,201,489 shares worth $14.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2745.

Ken Griffin first reported a position in TRVI in Q1 2021 and has held it in 15 quarters since. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • Ken Griffin held 1,201,489 shares of Trevi Therapeutics worth $14.3M as of Q1 2026.
  • Ken Griffin bought 1,048,634 Trevi Therapeutics shares in Q1 2026, an estimated $11.7M.
  • Trevi Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #2745 holding.
  • Ken Griffin first reported a position in Trevi Therapeutics in Q1 2021 and has held it in 15 quarters since.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.